Oyster Point Pharma to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference

Rhea-AI Summary

Oyster Point Pharma (Nasdaq: OYST) will participate in a live Q&A at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on September 18, 2020, at 8:00 a.m. ET. The company focuses on developing first-in-class therapies for ocular surface diseases, including its lead product, OC-01 nasal spray, designed to treat dry eye disease by activating the trigeminal parasympathetic pathway for tear film production. For the live webcast, visit the Investors and News section on their website.

PRINCETON, N.J., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that the Company will participate in a live Q&A at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on Friday, September 18, 2020 at 8:00 a.m. ET and host investor meetings.

To access the live webcast, please visit the “Investors and News” section of the Oyster Point Pharma website at https://investors.oysterpointrx.com/.

About Oyster Point Pharma
Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01 nasal spray, a highly selective cholinergic agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. OC-01 nasal spray’s novel mechanism of action re-establishes tear film homeostasis by activating the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit (LFU).

Investor Contact: 
Tim McCarthy 
LifeSci Advisors, LLC 
(212) 915-2564 
investors@oysterpointrx.com

Media Contact: 
Jeffrey Nau PhD, MMS 
President and Chief Executive Officer
media@oysterpointrx.com

FAQ

When will Oyster Point Pharma participate in the Morgan Stanley Healthcare Conference?

Oyster Point Pharma will participate in the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on September 18, 2020, at 8:00 a.m. ET.

What is Oyster Point Pharma's lead product candidate?

Oyster Point Pharma's lead product candidate is OC-01 nasal spray, aimed at treating dry eye disease.

How does OC-01 nasal spray work?

OC-01 nasal spray works by activating the trigeminal parasympathetic pathway to stimulate tear film production.

Where can I access the live webcast of the conference?

The live webcast can be accessed in the Investors and News section of Oyster Point Pharma's website.

What is the focus of Oyster Point Pharma?

Oyster Point Pharma is focused on discovering and developing pharmaceutical therapies for ocular surface diseases.